Overview of cancer incidence and mortality among people living with HIV/AIDS in British Columbia, Canada: Implications for HAART use and NADM development

Table 5 Association of clinical characteristics with development of NADM in PLWHA receiving antiretroviral therapy^a (n = 4918)

Clinical characteristic	Unadjusted Odds ratio	Adjusted Odds ratio^b
Clinical characteristic	(95% Confidence Intervals)	(95% Confidence Intervals)
Gender
Male	1.00 (−-)	---
Female	0.59 (0.35–0.98)	---
Age (years) at Start of Antiretroviral therapy
Under 50	1.00 (−-)	1.00 (--)
50 or more	4.32 (3.08–6.06)	4.03 (3.05–6.06)
Nadir CD4 (cells/mm³)
Less than 200	1.00 (−-)	1.00 (--)
200 or more	0.63 (0.42–0.95)	0.61 (0.41–0.93)
NADM Prior to Start of Antiretroviral Therapy^c
No	1.00 (−-)	1.00 (--)
Yes	4.87 (2.15–11.02)	3.42 (1.50–7.83)
Use of HAART^d
No	1.00 (−-)	1.00 (--)
Yes	0.76 (0.51–1.13)	0.64 (0.43–0.95)
Start of Antiretroviral Therapy^e
Early-HAART era (before 2000)	1.00 (−-)	---
Late-HAART era (2000 and after)	0.93 (0.31–1.34)	---

^aAmongst individuals with a NADM diagnosis compared to individuals without a NADM (represented by patients with either no cancer diagnosis [no ADM or NADM] or with an ADM only [but no NADM])
^bAdjusted odds ratio includes all variables listed under ‘Clinical Characteristic’ column. C-statistic = 0.689; multi-collinearity was verified and all variance inflation factors were less than 2
^cOnly individuals with diagnosis of NADM after initiation of antiretroviral therapy were included in the comparison groups. There were 6 patients in the group “Individuals with NADM” that had a NADM prior to antiretroviral treatment and developed a second NADM during anti-retroviral therapy
^dAll individuals were treated with antiretroviral therapy (monotherapy, dual therapy, or triple therapy); selected individuals were treated with HAART (triple therapy) according to guidelines at time of treatment
^eThe year cut-point was utilized to represent use of more efficient HAART starting in the year 2000

ISSN: 1471-2407